update- nudg pt
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
solid quarter even adjust tender contribut pre-juli purchas
may drive sell-off consist conserv guidanc
wouldnt surpris see anoth rais slight delay ahu file track
pnh approv slight delay wilson program file physician survey work show
encourag overwhelm interest still plenti time execut transit
updat model increas pt reiter outperform rate watch
capit alloc close increasingli focus stock base comp deplet cash flow
benefit order time juli soliri strensiq row tender
market
usual guidanc still look conserv even increas shown
non-gaap oper margin compress invest
highest number pnh addit sinc launch
mg adopt strong see higher respons rate real world clinic trial finish
patient enrol access program therapi cover live
access slower adopt germani due lack experi new sale initi
nmo studi last visit finish patient return final analysi databas lock come
month data later year
survey physician would switch all/som pnh patient saw spontan
opportun switch patient interest switch high confid abil
new formul reduc infus time minut
ahu studi expect earli file pnh approv
start mg later year file
file japan
start technology- name potenti dose
evalu superior standard care may add liver biopsi studi expand size
pt
enrol timelin extend expect file approv
increas pt maintain outperform rate
increas outer year revenu estim revenu reflect
minor adjust expens
track respect beat/miss
commentari around product serial around quarter includ
serial guidanc updat
line volum volum impact byidentif new patient us germani japan expect strensiq rev/pt lower see thatwork payor align valu higher dose yoy growth continu growth germani japannew patient germani japan fund agreement uk franc israel new fund agreement yoy revenu growth volum growthcontinu growth germani yoy revenu growth volum growthinclud order juli holidaykanumagrowth impact byexpand lab test target enrich pt pop higher likelihood lal-dsplit sale forc strensiq favor order ex-u market previous defer revexpand lab test yoy revenu growth volum growthtim order tender markets/def revenu benefit yoy revenu growth volum growthinclud order juli impact expir batch yoy favor impact tender order ou includ million order ahead juli mg launchalxn histor quarter perform commentaryadjust ep growthgrowth impact bysolirisadjust salesadjust sg salesoper unfavor impact million trial time benefit latam still underli challeng access new pt start pnh ahu mil impact competitor trialstot unfavor impact enrollment-eu apac impact vs price headwind fx headwind volum growth adjust benefit favor order neg impact trial minim contribut gmgnew patient start ahu pnh minim gmg contribut juli
soliri benefitsoliri limit mg contribut start later year earli mg launch total sg total oper margin total expect tax compani reportsannu revenu guidanc convert follow year juli
deriv valuat base dcf use discount rate appli commerci
stage biotech compani termin growth rate reflect optimist outlook durabl compani
franchis includ contribut soliri myasthenia gravi nmo given concern scientif merit
indic includ product revenu reflect potenti busi develop
risk price target includ intensifi competit threat formid biopharma compani along potenti
amplifi price pressur failur build compel develop pipelin stumbl develop
trial would expect litani downgrad substanti re-rat
articl articl
time dissemin juli et
analyst josh schimmer steven breazzano maneka mirchandaney ami liu shenston huang primarili respons
prepar research report attest follow view opinion render research report reflect
person view subject compani issuer part research analyst compens directli
relat specif recommend view research report
